Sanofi is a global integrated healthcare company focused on patients? needs with a diversified offer of medicines, vaccines and innovative therapeutic solutions, engaged in the research, development, manufacturing and marketing of healthcare products. As part of their oncology portfolio, the company?develops, manufactures and commercialize antibody drug conjugate (ADC), including?SAR3419, a novel anti-CD19 ADC. SAR3419 includes an anti-CD19 monoclonal antibody and a maytansine derivate. SAR3419 combines tubulin inhibition with the B-cell selectivity of an anti-CD19 antibody.

Clinical trials with SAR3419 include:

  • NCT01472887– SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients (STARLYTE)
  • NCT00796731?-?SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin’s Lymphoma/span>
  • NCT01440179 – SAR3419 in Acute Lymphoblastic Leukemia (MYRALL)
  • NCT00549185 – Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin’s Lymphoma
  • NCT01470456 – Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

55 Corporate Drive
Bridgewater, NJ 08807
U.S.A.

Web:?Sanofi Oncology

Advertisement #5